NCT03468790View on ClinicalTrials.gov

Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

PHASE3CompletedINTERVENTIONAL
Enrollment

393

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

January 12, 2021

Study Completion Date

March 9, 2021

Conditions
Asthma, Allergic
Interventions
DRUG

CMAB007

the study drug

DRUG

Symbicort

asthma-controlled drug

DRUG

Seretide

asthma-controlled drug

DRUG

Ventolin

asthma rescue drug

DRUG

placebo

No active components

Trial Locations (2)

325000

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

510030

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Shanghai Biomabs Pharmaceutical Co., Ltd.

INDUSTRY

NCT03468790 - Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. | Biotech Hunter | Biotech Hunter